Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

PedBrain Tumor network publishes evaluation of first 125 genome analyses of medulloblastomas

PedBrain Tumor network publishes evaluation of first 125 genome analyses of medulloblastomas

Fusion of FGFR and TACC gene leads to glioblastoma

Fusion of FGFR and TACC gene leads to glioblastoma

American Society of Hematology announces new grant program for biomedical research

American Society of Hematology announces new grant program for biomedical research

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Cepheid launches new Xpert BCR-ABL Monitor test

Cepheid launches new Xpert BCR-ABL Monitor test

NCCN Guidelines for Patients: Lung Cancer Screening now available free of charge

NCCN Guidelines for Patients: Lung Cancer Screening now available free of charge

JTCC to present latest findings in blood-cancer research at ASCO annual meeting

JTCC to present latest findings in blood-cancer research at ASCO annual meeting

ASH report urges federal agencies to invest in 7 distinct areas of research

ASH report urges federal agencies to invest in 7 distinct areas of research

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Longer looks: Rushed medicine; Exercising your way to a smarter brain

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

Novel anti-leukemia compound with little toxicity successfully treats zebrafish

Bio-Path 2011 net loss increases to $2,363,344

Bio-Path 2011 net loss increases to $2,363,344

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

East Asian BIM gene variant contributes to drug resistance in cancer

East Asian BIM gene variant contributes to drug resistance in cancer

CML patients can benefit from imatinib after unsuccessful interferon therapies

CML patients can benefit from imatinib after unsuccessful interferon therapies

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

Kedem commences development of Gleevec to treat CML in children and adults

Kedem commences development of Gleevec to treat CML in children and adults

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

D12-PGJ3 compound can cure leukemia

D12-PGJ3 compound can cure leukemia